Pancreatic cancer therapy could target lung cancer

A newly approved molecular glue designed to block mutated signaling proteins has produced tumor shrinkage in patients with advanced non-small-cell lung cancer, according to early clinical trial findings.

A molecular switch inside lung cells that was long considered unreachable by targeted medication can be jammed by pinning it to an ordinary cellular helper protein. For decades, oncologists struggled to shut down mutated signaling proteins belonging to the RAS family, which become stuck in an active state and continuously order lung cells to divide.¹² The physical surface of these proteins is remarkably smooth, leaving few deep pockets where conventional pill-based therapies can attach.¹ A newly developed oral drug overcomes that barrier by adhering to another ubiquitous cellular protein first, assembling a composite surface that clamps shut the aberrant signaling machinery.²¹

The therapeutic target matters because lung cancer remains the leading cause of cancer mortality worldwide, with non-small-cell lung cancer accounting for the vast majority of diagnoses.²³ Roughly 30 percent of non-small-cell lung cancer cases are driven by mutations in the RAS family of genes, most frequently the variant known as KRAS.³¹ When standard front-line treatments such as platinum-based chemotherapy and immunotherapy stop working, the disease almost always progresses, leaving patients with limited alternatives that offer brief survival extensions alongside severe physical toxicities.³¹

In healthy human tissue, cellular communication relies on an orderly chain of physical interactions. Receptors on the outer surface of a cell detect growth cues and transmit signals across the cell membrane to internal switchboard proteins called RAS. These proteins cycle between an inactive state and an active state, passing the instruction down molecular pathways to prompt cellular division. Once a signaling cycle finishes, the protein promptly switches off. In tumors with a mutated RAS gene, that shutoff mechanism breaks, locking the protein into an active configuration that constantly directs the cell to multiply. Daraxonrasib, an oral drug developed by the biotechnology company Revolution Medicines, intervenes by binding to cyclophilin A, an abundant structural protein found naturally inside human cells.²³ Together, the drug and cyclophilin A create a new molecular surface that binds to the active RAS switch, physically blocking it from interacting with downstream partner proteins that transmit growth instructions.²¹

According to clinical trial results published on September 2, 2026, in The New England Journal of Medicine, this molecular approach triggered objective tumor shrinkage in more than 30 percent of patients with pretreated non-small-cell lung cancer.¹ The finding indicates that an agent originally developed and approved for advanced pancreatic tumors can cross organ categories and attack identical genetic drivers lodged within lung tissue.²¹

Why did lung cancer mutations resist targeted treatment?

Mutated RAS proteins defied targeted drug design for more than three decades because their globular, shallow physical structures provided no accessible chemical anchor points for synthetic small molecules.² While modern oncology successfully introduced inhibitors that locked onto well-defined molecular grooves in other cancer drivers, RAS switches lacked the clefts and crevices that pharmaceutical chemists typically exploit. Even when the first targeted treatments reached clinics around 2021, those initial therapies only attached to one specific variant, KRAS G12C, leaving patients with other mutations without targeted options.

In a report published on September 2, 2026, by Memorial Sloan Kettering Cancer Center, Bill Piersol detailed that the trial investigated patients whose lung cancers were driven by diverse KRAS mutations, including the G12V, G12A, G12D, G13D, and Q61 alterations. Thoracic medical oncologist Kathryn Arbour at Memorial Sloan Kettering Cancer Center, who served as the lead author of the study, noted that daraxonrasib represents the first therapy capable of inhibiting all of the primary KRAS mutation variants identified in lung malignancies.¹² In an announcement released through the cancer center, Arbour explained that because different RAS mutations emerge across varied patient populations, including individuals who smoked as well as those who never smoked, a broad-acting inhibitor dramatically expands therapeutic possibilities.²

How does the new molecular therapy stop tumor growth?

Daraxonrasib stops tumor proliferation by serving as a molecular glue that joins an endogenous cellular protein to the oncogenic switch, physically blocking the switch from docking with downstream effectors.²¹ Rather than attempting to wedge directly into the smooth surface of the RAS protein alone, the small-molecule agent first attaches to cyclophilin A, a helper protein that assists with protein folding inside the cytoplasm.² The resulting drug-protein union creates a specialized binding face that accommodates both normal and mutated forms of the active RAS molecule. Once bound, the composite structure obstructs the docking sites through which RAS normally engages its signaling partners, depriving the cancerous cell of instructions to divide and multiply.²

The identical molecular mechanism achieved regulatory success in gastrointestinal oncology just one week before the lung trial results appeared.²¹ On August 26, 2026, the Food and Drug Administration approved daraxonrasib under the brand name Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma, an aggressive cancer arising from the epithelial cells lining the pancreatic ducts.⁴ In that randomized Phase 3 clinical trial of 500 patients, daraxonrasib reached a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy, as reported by the Office of the Commissioner at the Food and Drug Administration.⁵⁴² That survival improvement prompted regulatory clearance 6.5 months ahead of the agency deadline.⁵² Cancer researcher Channing Der at the University of North Carolina at Chapel Hill remarked in a Nature news report that the pancreatic data immediately raised the clinical question of whether the same inhibitory mechanism could be transferred to treat other malignancies.²

What do the clinical trial measurements reveal?

The early-phase clinical trial demonstrated that daraxonrasib achieved measurable tumor regression in a patient population whose cancer had advanced through multiple standard therapies.³¹ In the multi-center Phase 1/2 investigation, which enrolled 136 patients with metastatic non-small-cell lung cancer who had previously received systemic chemotherapy and immunotherapy, more than 30 percent experienced confirmed tumor reduction, according to data summarized by Memorial Sloan Kettering Cancer Center.¹²

A specific cohort of 38 patients evaluated at The University of Texas MD Anderson Cancer Center received daily doses ranging between 160 milligrams and 220 milligrams, the dosing window chosen for larger ongoing trials.³ In this group of 38 participants who had received prior platinum-based chemotherapy and immune checkpoint inhibitors, the objective response rate reached 42 percent, as reported by Aubrey Bloom for MD Anderson Research News. The median duration of tumor response among responding patients in this group was 11.5 months.³ Furthermore, median progression-free survival, defined as the duration during treatment before the malignancy resumed growth, reached 8.3 months, while median overall survival reached 16.0 months.³ By comparison, historical clinical trials evaluating standard second-line docetaxel chemotherapy in patients with pretreated RAS-mutated non-small-cell lung cancer have recorded objective response rates between 9 percent and 14 percent, median progression-free survival between 3.0 and 4.5 months, and median overall survival between 9.0 and 12.0 months.³

What questions remain before broader regulatory clearance?

The early findings cannot confirm whether daraxonrasib improves overall survival in a randomized comparison against the current standard of care, because the initial Phase 1/2 trial lacked a direct control group receiving chemotherapy.² Single-arm phase 1 and phase 2 trials serve to evaluate drug safety, establish tolerable dosing schedules, and measure initial anti-tumor activity, rather than providing definitive proof of comparative clinical superiority.¹³ Additionally, the experimental therapy produced noticeable physical toxicities across the study cohort, demonstrating that broader therapeutic reach introduces distinct clinical management challenges.³¹

Among the patients treated within the recommended Phase 3 dose range, 51 percent experienced an adverse event rated at grade 3 or higher, according to the MD Anderson trial analysis led by deputy chair of Investigational Cancer Therapeutics David Hong. Overall, 71 percent of those patients required dose modifications to manage adverse effects, and 10 percent discontinued the medication entirely due to treatment-related toxicity.³ The most common side effect was skin rash, which developed in 90 percent of participants, with 8 percent experiencing grade 3 severity.³ Gastrointestinal complications also occurred frequently: diarrhea affected 73 percent of patients, nausea affected 62 percent, and vomiting occurred in 54 percent, with each gastrointestinal condition showing a grade 3 incidence of less than 10 percent.³

Tumor resistance presents an additional scientific hurdle that early trial data cannot fully resolve. While the targeted therapy shrank tumors initially, multiple trial participants eventually experienced disease progression as their cancer developed resistance mechanisms against the drug.² The ongoing Phase 3 RASolve 301 trial, led by Ferdinandos Skoulidis at MD Anderson and Arbour at Memorial Sloan Kettering, is currently randomizing patients with non-small-cell lung cancer between daraxonrasib and standard docetaxel chemotherapy.¹² Initial data from that randomized study, anticipated in 2027, are expected to reveal whether the survival advantages observed in early cohorts hold across a larger population and clarify how long the molecular blockade holds before cancer cells evade it.³²

This piece was prepared from the paper in The New England Journal of Medicine and public records; the authors have not been interviewed.

What this rests on

36 sentences trace to 5 sources.

All 5Documents 2Records 1Reporting 2People 0

1. 1 MS Memorial Sloan Kettering Third-party reporting · mskcc.org · 2 Sep 2026 Potential New Treatment for Lung Cancer: Daraxonrasib Aimed at RAS Mutations | Memorial Sloan Kettering Cancer Center See the source
2. 2 U us.list-manage.com Document · us.list-manage.com Pancreatic drug could tackle lung cancer See the source
3. 3 UM UT MD Anderson Press release · mdanderson.org · 2 Sep 2026 Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer See the source
4. 4 S statnews.com Third-party reporting · statnews.com · 26 Aug 2026 FDA approves new pancreatic cancer drug expected to usher in new era of treatment See the source
5. 5 F FDA Official record · fda.gov FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer See the source